Vitamin D receptor activation in a diabetic-like environment: potential role in the activity of the endothelial pro-inflammatory and thioredoxin pathways.

The Journal of steroid biochemistry and molecular biology 20121001

VDRA therapy is associated with improved survival in dialysis patients with serum intact PTH ≤ 150 pg/mL: results of the Italian FARO Survey.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20120901

Suppressive effect of 19-nor-1α-25-dihydroxyvitamin D2 on gastric cancer cells and peritoneal metastasis model.

Journal of Korean medical science 20120901

Exposure-clinical response analysis of paricalcitol in patients with chronic kidney disease (stage 5) on hemodialysis or peritoneal dialysis.

Journal of clinical pharmacology 20120801

Paricalcitol versus cinacalcet plus low-dose vitamin D therapy for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: results of the IMPACT SHPT study.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20120801

Long-term management of CKD-mineral and bone disorder.

American journal of kidney diseases : the official journal of the National Kidney Foundation 20120801

Changes in peritoneal membrane permeability and proteinuria in patients on peritoneal dialysis after treatment with paricalcitol − a preliminary study.

Clinical nephrology 20120801

Antioxidant and renoprotective effects of paricalcitol on experimental contrast-induced nephropathy model.

The British journal of radiology 20120801

Vitamin D receptor activation and prevention of arterial ageing.

Nutrition, metabolism, and cardiovascular diseases : NMCD 20120701

Role of mitochondria in paricalcitol-mediated cytoprotection during obstructive nephropathy.

American journal of physiology. Renal physiology 20120615

The effect of vitamin D derivatives on vascular calcification associated with inflammation.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20120601

Changes in fibroblast growth factor 23 during treatment of secondary hyperparathyroidism with alfacalcidol or paricalcitol.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20120601

Paricalcitol prevents cisplatin-induced renal injury by suppressing apoptosis and proliferation.

European journal of pharmacology 20120515

Microalbuminuria, another use for paricalcitol? Our experience in advanced chronic kidney disease.

Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia 20120514

Paricalcitol versus cinacalcet plus low-dose vitamin D for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: study design and baseline characteristics of the IMPACT SHPT study.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20120501

Protective effect of paricalcitol on cyclosporine-induced renal injury in rats.

Transplantation proceedings 20120401

Beyond proteinuria: VDR activation reduces renal inflammation in experimental diabetic nephropathy.

American journal of physiology. Renal physiology 20120315

Efficacy and safety of paricalcitol therapy for chronic kidney disease: a meta-analysis.

Clinical journal of the American Society of Nephrology : CJASN 20120301

Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial.

JAMA 20120215

Vitamin D in chronic kidney disease: more questions than answers.

JAMA 20120215

A randomised clinical study of alfacalcidol and paricalcitol.

Danish medical journal 20120201

Converting to doxercalciferol capsules from intravenous paricalcitol or doxercalciferol.

Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation 20120101

Left ventricular periostin gene expression is associated with fibrogenesis in experimental renal insufficiency.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20120101

Paricalcitol versus ergocalciferol for secondary hyperparathyroidism in CKD stages 3 and 4: a randomized controlled trial.

American journal of kidney diseases : the official journal of the National Kidney Foundation 20120101

Effect of paricalcitol and GcMAF on angiogenesis and human peripheral blood mononuclear cell proliferation and signaling.

Journal of nephrology 20120101

Effect of combining an ACE inhibitor and a VDR activator on glomerulosclerosis, proteinuria, and renal oxidative stress in uremic rats.

American journal of physiology. Renal physiology 20120101

Efficacy and tolerability of intravenous paricalcitol in calcitriol-resistant hemodialysis patients with secondary hyperparathyroidism: 12-month prospective study.

Renal failure 20120101

Role of vitamin d receptor activators in cardio-renal syndromes.

Seminars in nephrology 20120101

Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).

PLoS computational biology 20111201

Short-term vitamin D receptor activation increases serum creatinine due to increased production with no effect on the glomerular filtration rate.

Kidney international 20111101

Short-term effects of vitamin D receptor activation on serum creatinine, creatinine generation, and glomerular filtration.

Kidney international 20111101

No difference between alfacalcidol and paricalcitol in the treatment of secondary hyperparathyroidism in hemodialysis patients: a randomized crossover trial.

Kidney international 20111001

New clinical trials with vitamin D and analogs in renal disease.

Kidney international 20111001

VS-105: a novel vitamin D receptor modulator with cardiovascular protective effects.

British journal of pharmacology 20110901

Preventing progression of cardiac hypertrophy and development of heart failure by paricalcitol therapy in rats.

Cardiovascular research 20110901

Differential effects of vitamin d receptor agonists on gene expression in neonatal rat cardiomyocytes.

Cardiovascular drugs and therapy 20110601

Paricalcitol in secondary hyperparathyroidism and the survival benefit in patients with chronic kidney disease.

Journal of renal care 20110601

The role of paricalcitol on proteinuria.

Journal of renal care 20110601

Achievement of recommended treatment targets for bone and mineral metabolism in haemodialysis patients using paricalcitol: an observational study.

Scandinavian journal of urology and nephrology 20110401

The use of group sequential, information-based sample size re-estimation in the design of the PRIMO study of chronic kidney disease.

Clinical trials (London, England) 20110401

Effect of paricalcitol and calcitriol on aortic wall remodeling in uninephrectomized ApoE knockout mice.

American journal of physiology. Renal physiology 20110301

Paricalcitol for reduction of albuminuria in diabetes.

Lancet (London, England) 20110219

Paricalcitol for reduction of albuminuria in diabetes.

Lancet (London, England) 20110219

Paricalcitol for reduction of albuminuria in diabetes.

Lancet (London, England) 20110219

Paricalcitol for reduction of albuminuria in diabetes.

Lancet (London, England) 20110219

Comparative effectiveness of paricalcitol versus cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis.

Nephron. Clinical practice 20110101

Blockade of Wnt/β-catenin signaling by paricalcitol ameliorates proteinuria and kidney injury.

Journal of the American Society of Nephrology : JASN 20110101

Calcific uremic arteriolopathy while on cinacalcet.

Journal of postgraduate medicine 20110101

Vitamin D receptor activation and left ventricular hypertrophy in advanced kidney disease.

American journal of nephrology 20110101

Comparative effectiveness of active oral vitamin D agents in patients on peritoneal dialysis.

Nephrology news & issues 20110101

Calcific uremic arteriolopathy treated with cinacalcet, paricalcitol, and autologous growth factors.

Journal of cutaneous medicine and surgery 20110101

[Paricalcitol: an ally against proteinuria in diabetic patients?].

Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia 20110101

Validated stability-indicating HPLC method for paricalcitol in pharmaceutical dosage form according to ICH guidelines: application to stability studies.

Journal of AOAC International 20110101

Secondary hyperparathyroidism in chronic dialysis patients: results of the Italian FARO survey on treatment and mortality.

Blood purification 20110101

Restoring the physiology of vitamin D receptor activation and the concept of selectivity.

Contributions to nephrology 20110101

The impact of paricalcitol on left ventricular hypertrophy.

Contributions to nephrology 20110101

[The role of D2 vitamin metabolite paricalcitol in nephroprotective strategy in chronic disease of the kidneys].

Terapevticheskii arkhiv 20110101

Effects of oral paricalcitol on hyperparathyroidism and proteinuria in peritoneal dialysis patients.

Advances in peritoneal dialysis. Conference on Peritoneal Dialysis 20110101

Effectiveness of treatment with oral paricalcitol in patients with pre-dialysis chronic kidney disease.

Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia 20110101

Paricalcitol, a synthetic vitamin D analog: a candidate for combination therapy with biological agents in rheumatoid arthritis.

Medical hypotheses 20101201

Increased fetuin-A levels following treatment with a vitamin D analog.

Kidney international 20101201

[Cutaneous calciphylaxis].

Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete 20101201

An economic comparison of surgical and medical therapy in patients with secondary hyperparathyroidism--the German perspective.

Surgery 20101201

Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial.

Lancet (London, England) 20101106

Into the light? Diabetic nephropathy and vitamin D.

Lancet (London, England) 20101106

Chondro/osteoblastic and cardiovascular gene modulation in human artery smooth muscle cells that calcify in the presence of phosphate and calcitriol or paricalcitol.

Journal of cellular biochemistry 20101101

Association of cumulatively low or high serum calcium levels with mortality in long-term hemodialysis patients.

American journal of nephrology 20101101

Effect of paricalcitol on the urinary peptidome of kidney transplant patients.

Transplantation proceedings 20101001

Therapeutic effects of vitamin D analogs on cardiac hypertrophy in spontaneously hypertensive rats.

The American journal of pathology 20100801

Kidney bone disease and mortality in CKD: revisiting the role of vitamin D, calcimimetics, alkaline phosphatase, and minerals.

Kidney international. Supplement 20100801

Treatment of secondary hyperparathyroidism in ESRD: a 2-year, single-center crossover study.

Kidney international. Supplement 20100801

Myocardial effects of VDR activators in renal failure.

The Journal of steroid biochemistry and molecular biology 20100701

Combined vitamin D analog and AT1 receptor antagonist synergistically block the development of kidney disease in a model of type 2 diabetes.

Kidney international 20100601

Effect of paricalcitol and cinacalcet on serum phosphate, FGF-23, and bone in rats with chronic kidney disease.

American journal of physiology. Renal physiology 20100601

Do calcimimetics directly alter bone remodeling?

American journal of physiology. Renal physiology 20100601

Paricalcitol attenuates cyclosporine-induced kidney injury in rats.

Kidney international 20100601

Are vitamin D receptor agonists like angiotensin-converting enzyme inhibitors without side effects?

Kidney international 20100601

The unsolved cyclosporine-induced kidney injury: is paricalcitol a feasible new renoprotective option?

Kidney international 20100601

Cholecalciferol supplementation in hemodialysis patients: effects on mineral metabolism, inflammation, and cardiac dimension parameters.

Clinical journal of the American Society of Nephrology : CJASN 20100501

New therapies: calcimimetics, phosphate binders and vitamin D receptor activators.

Pediatric nephrology (Berlin, Germany) 20100401

Use of 3-hour daily hemodialysis and paricalcitol in patients with severe secondary hyperparathyroidism: A case series.

Hemodialysis international. International Symposium on Home Hemodialysis 20100401

Paricalcitol reduces basal and lipopolysaccharide-induced (LPS) TNF-alpha and IL-8 production by human peripheral blood mononuclear cells.

International urology and nephrology 20100301

Renoprotective effects of paricalcitol on gentamicin-induced kidney injury in rats.

American journal of physiology. Renal physiology 20100201

Vitamin D receptor activators induce an anticalcific paracrine program in macrophages: requirement of osteopontin.

Arteriosclerosis, thrombosis, and vascular biology 20100201

Pivotal role of paricalcitol in the treatment of calcific uremic arteriolopathy in the presence of a parathyroid adenoma.

American journal of kidney diseases : the official journal of the National Kidney Foundation 20100101

Differential effects of paricalcitol and calcitriol on intestinal calcium absorption in hemodialysis patients.

American journal of nephrology 20100101

Calcium balance in dialysis is best managed by adjusting dialysate calcium guided by kinetic modeling of the interrelationship between calcium intake, dose of vitamin D analogues and the dialysate calcium concentration.

Blood purification 20100101

Cost Effectiveness of Paricalcitol versus a non-selective vitamin D receptor activator for secondary hyperparathyroidism in the UK: a chronic kidney disease markov model.

Clinical drug investigation 20100101

Effects of paricalcitol and enalapril on atherosclerotic injury in mouse aortas.

American journal of nephrology 20100101

[Ultrasound parameter-based response to treatment with new drugs for secondary hyperparathyroidism: a retrospective analysis in a single dialysis center].

Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia 20100101

[Role of paracalcitol in the management of non-dialysis CKD: state of art and... Unmet needs].

Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia 20100101

Combination therapy with paricalcitol and trandolapril reduces renal fibrosis in obstructive nephropathy.

Kidney international 20091201

Vitamin D: a new hope for chronic kidney disease?

Kidney international 20091201

Oral paricalcitol in the treatment of patients with CKD and proteinuria: a randomized trial.

American journal of kidney diseases : the official journal of the National Kidney Foundation 20091001

Paricalcitol (19-nor-1,25-dihydroxyvitamin D2) and calcitriol (1,25-dihydroxyvitamin D3) exert potent immunomodulatory effects on dendritic cells and inhibit induction of antigen-specific T cells.

Clinical immunology (Orlando, Fla.) 20091001

Intravenous calcitriol versus paricalcitol in haemodialysis patients with severe secondary hyperparathyroidism.

Nephrology (Carlton, Vic.) 20090801

Paricalcitol and outcome: a manual on how a vitamin D receptor activator (VDRA) can help us to get down the 'U'.

Clinical nephrology 20090601

Chronic kidney disease Markov model comparing paricalcitol to calcitriol for secondary hyperparathyroidism: a US perspective.

Current medical research and opinion 20090501

Battle against the renin-angiotensin system: help from an unexpected party.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20090401

The effect of paricalcitol on osteoprotegerin production by human peripheral blood mononuclear cells.

The Journal of rheumatology 20090401

Role of vitamin D in chronic kidney disease.

Seminars in nephrology 20090301

Paricalcitol and renin-angiotensin components in remnant kidneys.

Kidney international 20090201

Vitamin D receptor activators.

The International journal of artificial organs 20090201

Combination therapy with paricalcitol and enalapril ameliorates cardiac oxidative injury in uremic rats.

American journal of nephrology 20090101

Paricalcitol treatment of secondary hyperparathyroidism in hemodialysis patients on sevelamer hydrochloride: which dialysate calcium concentration to use?

Blood purification 20090101

Beneficial effects of better control of secondary hyperparathyroidism with paricalcitol in chronic dialysis patients.

Journal of nephrology 20090101

Importance of vitamin D receptor activation in clinical practice.

Contributions to nephrology 20090101

New acquisitions in therapy of secondary hyperparathyroidism in chronic kidney disease and peritoneal dialysis patients: role of vitamin D receptor activators.

Contributions to nephrology 20090101

The selective vitamin D receptor activator for albuminuria lowering (VITAL) study: study design and baseline characteristics.

American journal of nephrology 20090101

[Multiple peritrochanteric and pubic calcifications in a young woman on hemodialysis with severe renal osteodystrophy successfully treated with sevelamer+cinacalcet+paracalcitol combination therapy].

Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia 20090101

Treatment of secondary hyperparathyroidism in haemodialysis patients: a randomised clinical trial comparing paricalcitol and alfacalcidol.

BMC nephrology 20090101

Differential effects of vitamin D receptor activators on aortic calcification and pulse wave velocity in uraemic rats.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20081201

Suppression of renin-angiotensin gene expression in the kidney by paricalcitol.

Kidney international 20081201

Ratio of paricalcitol dosage to serum parathyroid hormone level and survival in maintenance hemodialysis patients.

Clinical journal of the American Society of Nephrology : CJASN 20081101

Vitamin D receptor ligand therapy in chronic kidney disease.

Clinical nephrology 20081001

Converting hemodialysis patients from intravenous paricalcitol to intravenous doxercalciferol - a dose equivalency and titration study.

Clinical nephrology 20081001

Paricalcitol inhibits renal inflammation by promoting vitamin D receptor-mediated sequestration of NF-kappaB signaling.

Journal of the American Society of Nephrology : JASN 20080901

Vitamin D receptor activators can protect against vascular calcification.

Journal of the American Society of Nephrology : JASN 20080801

Is activated vitamin D supplementation renoprotective?

Hypertension (Dallas, Tex. : 1979) 20080801

Paricalcitol reduces albuminuria and inflammation in chronic kidney disease: a randomized double-blind pilot trial.

Hypertension (Dallas, Tex. : 1979) 20080801

Combination of sodium thiosulphate, cinacalcet, and paricalcitol in the treatment of calciphylaxis with hyperparathyroidism.

The International journal of artificial organs 20080801

Perspectives on vitamin D therapy in chronic kidney disease.

Nephrology news & issues 20080701

Emerging role for the vitamin D receptor activator (VDRA), paricalcitol, in the treatment of secondary hyperparathyroidism.

Expert opinion on pharmacotherapy 20080401

Pathogenesis and treatment of secondary hyperparathyroidism in dialysis patients: the role of paricalcitol.

Current vascular pharmacology 20080401

19-nor-1 alpha,25-dihydroxyvitamin D2 (paricalcitol) inhibits the proliferation of human pancreatic cancer cells in vitro and in vivo.

Cancer biology & therapy 20080301

Calcium balance during calcitriol and paricalcitol administration in healthy humans.

International journal of clinical pharmacology and therapeutics 20080301

The effect of calcitriol, paricalcitol, and a calcimimetic on extraosseous calcifications in uremic rats.

Kidney international 20080201

Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis.

American journal of nephrology 20080101

Management of secondary hyperparathyroidism in stages 3 and 4 chronic kidney disease.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 20080101

Paricalcitol treatment and arterial tone in experimental renal insufficiency.

Nephron. Experimental nephrology 20080101

[Clinical advances in vascular calcification].

Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia 20080101

Elevated phosphorus modulates vitamin D receptor-mediated gene expression in human vascular smooth muscle cells.

American journal of physiology. Renal physiology 20071101

Whole or fragmentary information on parathyroid hormone?

Clinical journal of the American Society of Nephrology : CJASN 20071101

Opposite effects of calcitriol and paricalcitol on the parathyroid hormone-(1-84)/large carboxy-terminal-parathyroid hormone fragments ratio in patients with stage 5 chronic kidney disease.

Clinical journal of the American Society of Nephrology : CJASN 20071101

Relationship between vitamin D and muscle size and strength in patients on hemodialysis.

Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation 20071101

Paricalcitol aggravates perivascular fibrosis in rats with renal insufficiency and low calcitriol.

Kidney international 20071001

Differential effects of vitamin D receptor activators on vascular calcification in uremic rats.

Kidney international 20070901

Vascular calcification in chronic kidney disease: new developments in drug therapy.

Kidney international 20070901

Differential effects of vitamin D analogs on vascular calcification.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20070601

Combination therapy with an angiotensin-converting enzyme inhibitor and a vitamin D analog suppresses the progression of renal insufficiency in uremic rats.

Journal of the American Society of Nephrology : JASN 20070601

Intravenous paricalcitol for treatment of secondary hyperparathyroidism in children on hemodialysis.

American journal of kidney diseases : the official journal of the National Kidney Foundation 20070601

Outcomes of secondary hyperparathyroidism in chronic kidney disease and the direct costs of treatment.

Journal of managed care pharmacy : JMCP 20070601

[New Active vitamin D analogs and calcimimetics to control hyperparathyroidism in chronic renal failure].

Clinical calcium 20070501

VDR-mediated gene expression patterns in resting human coronary artery smooth muscle cells.

Journal of cellular biochemistry 20070415

Optimal paricalcitol starting dose for parathyroid hormone suppression in secondary hyperparathyroidism.

Nature clinical practice. Nephrology 20070401

Osteomalacia in a hemodialysis patient receiving an active vitamin D sterol.

Nature clinical practice. Nephrology 20070401

Survival differences between activated injectable vitamin D2 and D3 analogs.

Kidney international 20070401

Effect of omeprazole on the pharmacokinetics of paricalcitol in healthy subjects.

Biopharmaceutics & drug disposition 20070301

Vascular calcification in chronic kidney failure: role of vitamin D receptor.

Current opinion in investigational drugs (London, England : 2000) 20070301

Vitamin D analogs modulate the expression of plasminogen activator inhibitor-1, thrombospondin-1 and thrombomodulin in human aortic smooth muscle cells.

Journal of vascular research 20070101

Impact of kidney bone disease and its management on survival of patients on dialysis.

Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation 20070101

Comparative cost-benefit analyses of paricalcitol and calcitriol in stage 4 chronic kidney disease from the perspective of a health plan.

Clinical drug investigation 20070101

Management of secondary hyperparathyroidism in uremic patients: the role of the new vitamin D analogs.

Journal of nephrology 20070101

Long-term outcomes of cinacalcet and paricalcitol titration protocol for treatment of secondary hyperparathyroidism.

American journal of nephrology 20070101

Managing bone parameters in dialysis patients: international guideline conflicts.

Seminars in dialysis 20070101

Differential inhibition of renin mRNA expression by paricalcitol and calcitriol in C57/BL6 mice.

Nephron. Physiology 20070101

Vitamin D receptor activator selectivity in the treatment of secondary hyperparathyroidism: understanding the differences among therapies.

Drugs 20070101

Nonclassical aspects of differential vitamin D receptor activation: implications for survival in patients with chronic kidney disease.

Drugs 20070101

Health-economic comparison of paricalcitol, calcitriol and alfacalcidol for the treatment of secondary hyperparathyroidism during haemodialysis.

Clinical drug investigation 20070101

Paricalcitol attenuates renal interstitial fibrosis in obstructive nephropathy.

Journal of the American Society of Nephrology : JASN 20061201

Calcification inhibitors and Wnt signaling proteins are implicated in bovine artery smooth muscle cell calcification in the presence of phosphate and vitamin D sterols.

Calcified tissue international 20061201

Mortality risk among hemodialysis patients receiving different vitamin D analogs.

Kidney international 20061101

Paricalcitol versus calcitriol treatment for hyperparathyroidism in pediatric hemodialysis patients.

Pediatric nephrology (Berlin, Germany) 20061001

Parathyromatosis and the challenge of treatment.

American journal of kidney diseases : the official journal of the National Kidney Foundation 20060901

Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients.

Kidney international 20060801

Initial dosing of paricalcitol based on PTH levels in hemodialysis patients with secondary hyperparathyroidism.

American journal of kidney diseases : the official journal of the National Kidney Foundation 20060701

Does paricalcitol reduce proteinuria in patients with chronic kidney disease?

Nature clinical practice. Nephrology 20060701

Paricalcitol for treatment of secondary hyperparathyroidism in CKD patients.

American journal of kidney diseases : the official journal of the National Kidney Foundation 20060601

Effects of Vitamin D analogs on gene expression profiling in human coronary artery smooth muscle cells.

Atherosclerosis 20060501

19nor-1,25-dihydroxyvitamin D2 specifically induces CYP3A9 in rat intestine more strongly than 1,25-dihydroxyvitamin D3 in vivo and in vitro.

Molecular pharmacology 20060501

Differential effects of very high doses of doxercalciferol and paricalcitol on serum phosphorus in hemodialysis patients.

Clinical nephrology 20060501

Paricalcitol [19-nor-1,25-(OH)2D2] in the treatment of experimental renal bone disease.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20060501

Paricalcitol capsules for the control of secondary hyperparathyroidism in chronic kidney disease.

Expert opinion on pharmacotherapy 20060401

Vitamin D receptor (VDR) localization in human promyelocytic leukemia cells.

Leukemia & lymphoma 20060401

Vitamin D and acute promyelocytic leukemia.

Leukemia & lymphoma 20060401

Cardiovascular disease in chronic kidney failure: the role of VDR activators.

Current opinion in investigational drugs (London, England : 2000) 20060301

Cinacalcet hydrochloride (Sensipar) in hemodialysis patients on active vitamin D derivatives with controlled PTH and elevated calcium x phosphate.

Clinical journal of the American Society of Nephrology : CJASN 20060301

Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD.

American journal of kidney diseases : the official journal of the National Kidney Foundation 20060201

Differential effects of Vitamin D analogs on bone formation and resorption.

The Journal of steroid biochemistry and molecular biology 20060101

Effects of vitamin D analogs on the expression of plasminogen activator inhibitor-1 in human vascular cells.

Thrombosis research 20060101

The effect of hepatic insufficiency on the safety and pharmacokinetics of paricalcitol (Zemplar).

Nephron. Clinical practice 20060101

A comparison of dosing regimens of paricalcitol capsule for the treatment of secondary hyperparathyroidism in CKD stages 3 and 4.

American journal of nephrology 20060101

[Inappropriate commercial presentation of selected drugs and associated overcost].

Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria 20060101

Therapy of secondary hyperparathyroidism to date: vitamin D analogs, calcimimetics or both?

Journal of nephrology 20060101

Health-economic comparison of paricalcitol, calcitriol and alfacalcidol for the treatment of secondary hyperparathyroidism during haemodialysis.

Clinical drug investigation 20060101

Antitumor effects of two less-calcemic vitamin D analogs (Paricalcitol and QW-1624F2-2) in squamous cell carcinoma cells.

Oncology 20060101

Phase I/II study of 19-nor-1alpha-25-dihydroxyvitamin D2 (paricalcitol) in advanced, androgen-insensitive prostate cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research 20051215

Antiproteinuric effect of oral paricalcitol in chronic kidney disease.

Kidney international 20051201

Vitamin D(2) analog (Paricalcitol; Zemplar) for treatment of myelodysplastic syndrome.

Leukemia research 20051101

Vitamin D analogs down-regulate plasminogen activator inhibitor-1 in human coronary artery smooth muscle cells.

Journal of thrombosis and haemostasis : JTH 20050701

Once-weekly intravenous paricalcitol in the treatment of secondary hyperparathyroidism in hemodialysis patients.

Clinical nephrology 20050601

Prediction of genotoxicity of chemical compounds by statistical learning methods.

Chemical research in toxicology 20050601

Activated injectable vitamin D and hemodialysis survival: a historical cohort study.

Journal of the American Society of Nephrology : JASN 20050401

19-Nor-1,25(OH)2D2 (a novel, noncalcemic vitamin D analogue), combined with arsenic trioxide, has potent antitumor activity against myeloid leukemia.

Cancer research 20050315

Are new vitamin D analogues in renal bone disease superior to calcitriol?

Pediatric nephrology (Berlin, Germany) 20050301

Cardiovascular disease in chronic kidney failure: is there a role for vitamin D analogs?

Current opinion in investigational drugs (London, England : 2000) 20050301

Paricalcitol: a review of its use in the management of secondary hyperparathyroidism.

Drugs 20050101

Spotlight on paricalcitol in secondary hyperparathyroidism.

Treatments in endocrinology 20050101

[New therapeutic strategies in secondary hyperparathyroidism on dialysis (II): vitamin D analogues and calcium-mimetics].

Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia 20050101

Vitamin D treatment in chronic kidney disease.

Seminars in dialysis 20050101

Inhibition of parathyroid hormone: a dose equivalency study of paricalcitol and doxercalciferol.

American journal of nephrology 20050101

Production of plasminogen activator inhibitor-1 (PAI-1) by endothelial cells: differential responses to calcitriol and paricalcitol.

Journal of thrombosis and haemostasis : JTH 20041201

Industry probe. Justice Department subpoenas dialysis providers.

Modern healthcare 20041101

Topical paricalcitol (19-nor-1 alpha,25-dihydroxyvitamin D2) is a novel, safe and effective treatment for plaque psoriasis: a pilot study.

The British journal of dermatology 20040701

Paricalcitol-treated patients experience improved hospitalization outcomes compared with calcitriol-treated patients in real-world clinical settings.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20040501

[The trend in the development of the active vitamin D3 and its analogues].

Nihon rinsho. Japanese journal of clinical medicine 20040501

Vitamin D analogs as therapeutic agents: a clinical study update.

Current opinion in investigational drugs (London, England : 2000) 20040301

Calcimimetics versus vitamin D: what are their relative roles?

Blood purification 20040101

Paricalcitol, calcitriol, and survival of patients undergoing hemodialysis.

The New England journal of medicine 20031113

Paricalcitol, calcitriol, and survival of patients undergoing hemodialysis.

The New England journal of medicine 20031113

Paricalcitol, calcitriol, and survival of patients undergoing hemodialysis.

The New England journal of medicine 20031113

1alpha,25-dihydroxyvitamin D(3) (calcitriol) and its analogue, 19-nor-1alpha,25(OH)(2)D(2), potentiate the effects of ionising radiation on human prostate cancer cells.

British journal of cancer 20030818

Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy.

The New England journal of medicine 20030731

Paricalcitol as compared with calcitriol in patients undergoing hemodialysis.

The New England journal of medicine 20030731

Vitamin D2 analog 19-nor-1,25-dihydroxyvitamin D2: antitumor activity against leukemia, myeloma, and colon cancer cells.

Journal of the National Cancer Institute 20030618

Efficacy of 19-Nor-1,25-(OH)2D2 in the prevention and treatment of hyperparathyroid bone disease in experimental uremia.

Kidney international 20030601

A strategy for the treatment of calcific uremic arteriolopathy (calciphylaxis) employing a combination of therapies.

Clinical nephrology 20030601

Long-term therapy with paricalcitol for secondary hyperparathyroidism in hemodialysis patients.

The International journal of artificial organs 20030601

Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism.

Kidney international 20030401

The renal dietitian's role in managing hyperphosphatemia and secondary hyperparathyroidism in dialysis patients: a national survey.

Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation 20030401

19-nor-1alpha,25-dihydroxyvitamin D(2) (paricalcitol): effects on clonal proliferation, differentiation, and apoptosis in human leukemic cell lines.

Journal of cancer research and clinical oncology 20030101

[Differential effect of vitamin D analogues on the proliferation of vascular smooth muscle cells].

Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia 20030101

[Mechanism of uremic osteodystrophy and prevention of hyperparathyroidism in the uremic patient].

Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia 20030101

Effects of 'non-calcaemic' vitamin D analogues on 24-hydroxylase expression in MG-63 osteoblast-like cells.

Nephron. Physiology 20030101

Severe hyperparathyroidism despite paricalcitol therapy: one-year follow-up.

Advances in peritoneal dialysis. Conference on Peritoneal Dialysis 20030101

Differential effects of acute administration of 19-Nor-1,25-dihydroxy-vitamin D2 and 1,25-dihydroxy-vitamin D3 on serum calcium and phosphorus in hemodialysis patients.

American journal of kidney diseases : the official journal of the National Kidney Foundation 20021201

Differential effects of 19-nor-1,25-(OH)(2)D(2) and 1alpha-hydroxyvitamin D(2) on calcium and phosphorus in normal and uremic rats.

Kidney international 20021001

Distal calcific uremic arteriolopathy in a hemodialysis patient responds to lowering of Ca x P product and aggressive wound care.

Clinical nephrology 20020901

Differential effects of 19-nor-1,25-dihydroxyvitamin D(2) and 1,25-dihydroxyvitamin D(3) on intestinal calcium and phosphate transport.

The Journal of laboratory and clinical medicine 20020501

Vitamin D analogs for the treatment of secondary hyperparathyroidism.

Blood purification 20020101

Comparative review of the pharmacokinetics of vitamin D analogues.

Seminars in dialysis 20020101

Transcriptional control of intestinal cytochrome P-4503A by 1alpha,25-dihydroxy vitamin D3.

Molecular pharmacology 20011201

Strategies to minimize bone disease in renal failure.

American journal of kidney diseases : the official journal of the National Kidney Foundation 20011201

p21WAF1 and TGF-alpha mediate parathyroid growth arrest by vitamin D and high calcium.

Kidney international 20011201

Severe secondary hyperparathyroidism.

Nephrology nursing journal : journal of the American Nephrology Nurses' Association 20011201

Vitamin D analogues for the management of secondary hyperparathyroidism.

American journal of kidney diseases : the official journal of the National Kidney Foundation 20011101

Paricalcitol in dialysis patients with calcitriol-resistant secondary hyperparathyroidism.

American journal of kidney diseases : the official journal of the National Kidney Foundation 20011101

Suppression of parathyroid hormone secretion in hemodialysis patients: comparison of paricalcitol with calcitriol.

American journal of kidney diseases : the official journal of the National Kidney Foundation 20011101

Paricalcitol dosing according to body weight or severity of hyperparathyroidism: a double-blind, multicenter, randomized study.

American journal of kidney diseases : the official journal of the National Kidney Foundation 20011101

A placebo-controlled trial to evaluate immunomodulatory effects of paricalcitol.

American journal of kidney diseases : the official journal of the National Kidney Foundation 20011001

A long-term, multicenter study of the efficacy and safety of paricalcitol in end-stage renal disease.

Clinical nephrology 20011001

Relative potencies of 1,25-(OH)(2)D(3) and 19-Nor-1,25-(OH)(2)D(2) on inducing differentiation and markers of bone formation in MG-63 cells.

Journal of the American Society of Nephrology : JASN 20010701

In vitro metabolism of 19-nor-1alpha, 25-(OH)2D2 in cultured cell lines: inducible synthesis of lipid- and water-soluble metabolites.

Archives of biochemistry and biophysics 20010315

[The stereocontrolled synthesis of 1-acetylenyl-3-tert-butyldiphenylsilyloxy-exo-bicyclo [3. 1. 0] hexane].

Hua xi yi ke da xue xue bao = Journal of West China University of Medical Sciences = Huaxi yike daxue xuebao 20010301

Calcitriol directly sensitizes renal tubular cells to ATP-depletion- and iron-mediated attack.

The American journal of pathology 19990601